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Abstract
Background: Treatment of depression, the most prevalent and costly mental disorder, needs to
be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of
pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve
patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and cost-
effectiveness of a community pharmacist intervention developed to improve adherence and
outcomes of primary care patients with depression.
Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients
receiving a pharmaceutical care support programme in primary care with patients receiving usual
care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive
disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked
for written informed consent in order to participate in the study. Diagnosis will be confirmed using
the SCID-I. The intervention consists of an educational programme focused on improving
knowledge about medication, making patients aware of the importance of compliance, reducing
stigma, reassuring patients about side-effects and stressing the importance of carrying out general
practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main
outcome measure is compliance with antidepressants. Secondary outcomes include; clinical
severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D),
satisfaction with the treatment received, side-effects, chronic physical conditions and socio-
demographics. The use of healthcare and social care services will be assessed with an adapted
version of the Client Service Receipt Inventory (CSRI).
Discussion: This trial will provide valuable information for health professionals and policy makers
on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the
context of primary care.
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One of the main challenges of public health is to improve
the treatment of depression. In fact, major depressive epi-
sode is one of the most prevalent mental disorders, both
in the general population [1-3] and in primary care [4],
and is one of the five mental disorders that cause the high-
est impairment, even higher than the ones associated with
chronic physical conditions [5-7]. Furthermore, it is the
most costly brain disorder in Europe, accounting for 33%
of the total cost [8]. Even though pharmacological treat-
ment in major depressive episodes is mostly prescribed as
recommended by Spanish primary care physicians, per-
centages of treatment concordance with clinical guide-
lines are low (between 21% and 25%) mainly because
recommended follow-up sessions are not performed [9].
Moreover, adherence to antidepressant medication is
poor [10], which could limit its effectiveness in clinical
practice. The World Health Organization and the Euro-
pean Council have stressed the importance of including
community pharmacists, considered the health profes-
sional most readily accessible to patients, as an active
member of the multidisciplinary healthcare team with the
aim of benefiting patients' health [11,12], including those
suffering from mental disorders [13].
By means of pharmaceutical care, community pharma-
cists have been shown to improve patient wellbeing in
chronic physical conditions such as diabetes mellitus [14]
and hypertension [15].
Research has been done to evaluate the effect of pharma-
ceutical care among outpatients diagnosed with depres-
sion [16-21] but in only three of the studies was the
intervention conducted by a community pharmacist [16-
18] and only one of them took place in a European coun-
try [16]. This was the only study that reported cost analysis
information [22]. The results provided by these studies are
contradictory and still more research is needed in order to
study this issue. The aim of this study is to evaluate the
efficacy of a pharmaceutical care programme, compared
with usual care, on the improvement of adherence to anti-
depressant drugs and patient wellbeing in a population
with a diagnosis of depression treated in primary care
under real practice circumstances. Programme cost-effec-
tiveness will be also calculated.
Methods/design
We followed the CONSORT statement for reporting rand-
omized trials [23].
6 month follow-up naturalistic randomized controlled
trial with random allocation of participants into two alter-
native branches: 1) Usual medical and pharmaceutical
care plus support programme in community pharmacy
(intervention group), and 2) Usual medical and pharma-
ceutical care (control group) (Figure 1).
The evaluation of compliance and clinical improvement
of participants will be carried out by individual assess-
ment at baseline, 3 and 6 months after the beginning of
the intervention.
The Clinical Research Ethics Committee of the Founda-
tion Sant Joan de Déu (CEIC Fundación SJD) approved the
study protocol (Reference Number: BECAFIS04/07). Par-
ticipants are only allowed to enter the study after signed
informed consent has been obtained.
Setting
Gavà is a city situated in the province of Barcelona (Cata-
lonia, Spain) approximately 15 kilometres south of Barce-
lona city. With a total area of 30.9 square kilometres and
a population of more than 45,000 inhabitants, the city
has two primary care health centres (PCHCs) (Gavà-1 and
Gavà-Doctor Bartomeu Fabrés Anglada) that provide
medical care to the whole population of Gavà. Patients
will be recruited at those PCHCs from October 2008 to
October 2009. 23 general practitioners (GPs) from the
PCHCs voluntarily participate in the study and deal with
the identification and subsequent recruitment of the
patients.
Altogether there are 14 community pharmacies in Gavà
that were asked to participate in the study. In addition,
there is a community pharmacy in the adjacent town of
Viladecans located very near to one of the PCHCs that was
also asked to participate. Two of the pharmacies (13%)
refused to participate, one citing heavy workload and the
other a lack of interest in the study. Finally, 13 pharmacies
with a total of 34 pharmacists will be responsible for pro-
viding patients with the intervention and usual care dur-
ing the 6 month follow-up period.
Enrolment, randomization and allocation
All patients initiating a treatment with any antidepressant
due to a depressive disorder through medical prescription
from a PCHC GP in Gavà, and who are aged 18–75, are
candidates for inclusion in the study. The following
patients will be excluded: those on antidepressant medi-
cation in the past 2 months, those who had an appoint-
ment with an specialist in mental health in the past 2
months, those with history of psychotic or bipolar disor-
ders, those with history of drug abuse or dependency,
those with cognitive impairment that prevents assessment
interviews, and those attending a pharmacy not included
in the study. The eligibility criteria are listed in Table 1.
Patients meeting the inclusion criteria are given the infor-
mation about the study's aim and procedures during thePage 2 of 8
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With the informed consent, the GP registers the patient's
telephone number and PCHC clinical-history reference
number. Within a week of the inclusion date, baseline
assessment is performed at the PCHC by a trained psy-
chologist.
Randomization was generated at the patient level by a
computerized random-number generator following a per-
muted block design. Block size was of 10 patients with a
ratio of 1:1. To assure the concealment of allocation, every
GP receives a set of 10 sequentially numbered, opaque,
sealed envelopes containing patient assignment. Enve-
lopes were generated by an external investigator and
details of the series are unknown to any of the GPs or
pharmacists in the study. As patients are enrolled, the GP
sequentially staples one of the envelopes to the prescrip-
tion. When the patient gives the prescription to their com-
munity pharmacist, they open the envelope and create a
patient study chart distinguishing between control and
intervention group.
Blinding of participants and pharmacists is not possible
because of the type of intervention. However, the assess-
ment visits and data analysis are conducted by independ-
ent and blinded evaluators.
Intervention and usual care
Patients in the intervention group will receive the support
programme in community pharmacy (PRODEFAR) every
time they go to the pharmacy to pick up the medication or
to ask for counselling in the course of the 6 months of the
study. Pharmacists participating in the study received 8
hours of training about PRODEFAR prior to the study. The
training followed a manual created for the study and is
accredited by the Catalonian council of continuous phar-
maceutical training (Consell Català de la formació farmacèu-
tica contínua) (Reference Number: 09F00676).
PRODEFAR consists of a series of educational interven-
tions focused on improving patients' knowledge of anti-
depressant medication, as well as making patients aware
of the importance of compliance to the medication. More-
over, in patients with a sceptical attitude towards the med-
ication, the intervention will aim to reduce stigma,
reassure the patient about possible side-effects, and stress
the importance of carrying out GPs' advice. First contact in
the PRODEFAR is expected to take between 20 and 30
minutes, subsequent interventions are expected to take
between 10 and 15 minutes.
Regardless of whether participants belong to the interven-
tion group or not, they receive the usual pharmaceutical
Study designFigure 1
Study design.
Assessment for eligibility
Randomization
Intervention group Control group
First contact
Pharmacist intervention
(20-30 minutes)
Usual care
Follow-up contacts
Pharmacist intervention
(10-15 minutes)
Baseline
assessment
(week 1)
3rd month 
assessment
6th month
assessmentPage 3 of 8
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by their physician. Patients receiving usual care get ordi-
nary advice about medication when collecting it. Any con-
cerns and questions addressed to the pharmacist are also
answered.
Patients in the intervention group are asked to avoid con-
versations concerning the PRODEFAR with patients from
the control group. The importance of this requirement is
emphasised to patients from both groups at baseline
assessment.
Measurements
Three assessment visits – at baseline, 3 and 6 months – are
conducted by independent and blinded interviewers. Par-
ticipants, pharmacists and GPs are not blinded. To limit
bias, two trained psychologists conduct all the interviews.
ASB and MRV were responsible for the interviewers' train-
ing. Table 2 shows the measures taken at each assessment
study visit.
Clinical diagnosis is made using the research version of
the Structured Clinical Interview for DSM-IV Axis I Disor-
ders (SCID-I) [24,25]. Patients are interviewed in the
modules of major depression (present and past), dys-
thymic disorder, anxiety disorder and adjustment disor-
der as defined according to DSM-IV criteria. Due to the
pragmatic character of the study, GPs are blind to the
DSM-IV diagnosis and patient inclusion and follow-up is
performed according to their usual practice.
The primary outcome measure of our study is adherence
to prescribed antidepressant medications, which is
assessed through two methods:
1) pharmacy records: every time a patient buys their med-
ication, the pharmacist registers the date of prescription,
the date of dispensation and the number of pills dis-
pensed. At 3 and 6 months from baseline, the patient is
asked to present the stock of antidepressant medication
and any surplus antidepressants following a GP recom-
mended change in medication. To minimize bias, the
patient is not told that the aim is to assess compliance.
The pharmacist registers the stock of every medication and
the percentage of medication intake is calculated by for-
mula: (Number of doses removed/Number of doses pre-
scribed)*100. Poor adherence is defined as taking less
than 80% of the prescribed doses. There are two disadvan-
tages of measuring adherence this way: the patient can
remove pills but not take them, and this formula does
provide information about the timing of the dose
removal.
2) self-reported: adherence to prescribed antidepressant
medications is assessed with the 4-item scale developed
by Morisky et al [26]. The scale asks patients to respond
"yes" or "no" to a set of 4 questions. A positive response
to any question indicates a problem with adherence.
Patients who respond "yes" to any of the items are catego-
rized as non-adherent.
Clinical severity of depression is measured with the
Patient Health Questionnaire 9-item depression module
(PHQ-9) [27-29]. The PHQ-9 is a nine-item scale that
assesses the depression symptoms of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV). Each of
the nine items is scored from 0, not at all, to 3, nearly
every day. The PHQ-9 can be used as a screening tool, with
summed score ranging from 0 (no depressive symptoms)
to 27 (all symptoms occurring daily). Summed scores of 0
to 4 correspond to minimal symptoms; 5 to 9 to mild
symptoms; 10 to 14 to moderate symptoms, 15 to19 to
moderately severe; and 20 to 27 to severe symptoms.
As mental disorders have been shown to be frequently
comorbid in the general population in Spain, and the
association between major depression and anxiety has
been especially highlighted [4,30], it is recommended that
comorbidity be taken into account when treating mental
disorders. The State-Trait Anxiety Inventory (STAI)
[31,32] is a 40 item self-report measure of state and trait
anxiety. Total scores on the state subscale (STAI-S) (20
items) range between 0 and 60, with the higher scores
indicating more severe state anxiety. STAI-S is adminis-
tered in the present research to monitor comorbidity with
depression and anxiety clinical severity.
Table 1: Eligibility criteria
Patients...
aged between 18 and 75,
initiating a pharmaceutical antidepressant treatment due to a depressive disorder through a medical prescription from a GP,
going to one of the participant community pharmacies,
that did not take antidepressant medication in the previous 2 months,
that have not had an appointment with an specialist in mental disorders in the previous 2 months,
with no history of psychotic or bipolar disorders,
with no history of drug abuse or dependency,
with no cognitive impairment that prevents assessment.Page 4 of 8
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ish version of the EuroQol-5D (EQ-5D) [33-35]. The EQ-
5D questionnaire is a generic instrument of health-related
quality-of-life. The first of the two parts records self-
reported problems in one of five domains-mobility, self-
care, usual activities, pain/discomfort and anxiety/depres-
sion-divided into three levels of severity corresponding to;
no problems, some problems, and extreme problems,
thus generating 245 possible health states [36]. Each state
corresponds to a single index value referred to as the tariff.
Value 1.000 is the best health state and value 0.000 corre-
sponds to being dead, 82 of the 245 states have negative
values, and are thus rated as being worse than dead [36].
The second part records the subject's self-assessed health
on a Visual Analogue Scale (VAS); a vertical 20 cm line on
which the best and worst imaginable health states score
100 and 0, respectively.
Satisfaction with the treatment received from the pharma-
cist is measured with the patient satisfaction question-
naire developed by Armando PD et al [37]. This
instrument consists of 10 closed questions using a 5-point
Likert scale from 1 (total disagreement) to 5 (strong agree-
ment) and an open section to express comments.
Evident side-effects are assessed using a brief version of
the UKU [38] considering the most common side-effects
of antidepressants. Those side-effects are listed in Table 3.
For each side-effect the intensity (Not present, mild, mod-
erate, or severe), frequency (high or low) and causal rela-
tion with antidepressant drugs (yes, no, or unclear) is
assessed.
Chronic physical conditions are assessed using a "yes" or
"no" check-list of 28 illnesses with the potential to
become chronic, and an open section for additional ill-
nesses not considered by the authors of the list [39]. Phys-
ical conditions considered chronic are listed in Table 4.
Additionally, patients are asked for socio-demographic
details including age, sex, marital status, living arrange-
ments, education, employment and type of contract.
Economic evaluation
Client Service Receipt Inventory (CSRI) [40] is a question-
naire for collecting information about use of healthcare
and social care services as well as other economic impacts.
In our study, we adapted it to take into account the costs
due to lost production as well as the cost of medicines, the
costs of healthcare use and social care services, and the
costs for patient in terms of travelling expenses and time
lost. Patients are asked to give details of services and med-
icines that they have used during the previous 3 months
due to depression or for other reasons. Services included
hospital care, primary healthcare and social care, as well
as the provision of aids, tests and medication. The length
of stay is recorded for inpatient episodes, whilst the
number of contacts with other services is recorded.
Table 2: Measurement scheme
Instrument T0 T1 T2
Baseline measures
Socio-demographics Questionnaire X
Psychiatric diagnosis SCID-I X
Chronic physical conditions Check list X
Effect evaluation
Compliance Medication intake percentage Continuous registration
Compliance MAQ X X
Severity of depression PHQ-9 X X X
Health-related quality of life EuroQOL-5D X X X
Anxiety (state) STAI-S X X X
Side-effects Check-list X X
Satisfaction Armando PD questionnaire X X
Economic evaluation
Direct and indirect costs CSRI – adapted X X X
T0 = Baseline, T1 = 3 months after baseline, T2 = 6 months after baseline.
SCID-I: Structured Clinical Interview Axis I DSM-IV; MAQ: Medication Adherence questionnaire; PHQ-9: Patient Health Questionnaire 9-item 
depression module; EuroQOL-5D: European Quality of Life Scale – 5 domains; STAI-S: State-Trait Anxiety Inventory (State subscale); CSRI: Client 
Service Receipt Inventory.Page 5 of 8
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To calculate the sample size it was taken into account that
we needed to obtain a difference of at least 17 points in
the percentage of medication intake [16]. A total of 194
patients are needed to conduct the study, assuming an
alpha risk of 0.05 and a beta risk of < 0.20 and a 20%
dropout rate.
Statistic analysis
Data collected will be analyzed using SPSS-WIN 17.0 and
SAS 8.0 statistical analysis software and employs both
quantitative and qualitative techniques. Firstly, compara-
bility between the intervention and usual-care groups will
be assessed at baseline to check differences.
Effect evaluation
Data will be primarily analyzed according to the intention
to treat principle (ITT), including all participants with
valid data regardless of whether they did or did not receive
the intervention. In addition, results will be analyzed
according to the on-treatment principle. Participants with
documented deviations from the protocol (i.e. false inclu-
sions, participants who did not receive the entire interven-
tion or participants in either the intervention or the
control group with incomplete follow-up data) will be
excluded from the on-treatment analysis. The results of
the ITT analysis will be compared with the results of the
on-treatment analysis to assess whether protocol viola-
tions have caused bias.
Economic evaluation
In order to compare the two therapeutic programmes, a
cost-effectiveness analysis will be performed. Direct costs
will be calculated by adding the costs of the medication,
the use of health-related services and the use of pharma-
ceutical-related services. According to the International
Vademecum (Red Book) 2007–2009, the cost of medica-
tions will be calculated by determining the price per mil-
ligram during the study, including value-added tax, and
multiplying it by the daily dose in milligrams and the
number of days receiving such treatment. Costs derived
from the use of health related services will be calculated
considering OBLIKUE unitary cost database [41]. Costs of
pharmaceutical related services will be calculated by mul-
tiplying the price of an hour of pharmacist attention by
the time spent attending patient concerns and needs.
Indirect costs will be calculated considering the days on
sick leave and multiplying them by the minimum daily
wage in Spain. Finally, total costs will be calculated by
adding direct and indirect costs.
Adherence to pharmacological treatment will be used to
compare the benefits of each intervention. To determine
which of the interventions is best for maximizing benefits,
the incremental cost-effectiveness ratio (ICER) will be cal-
culated. The ICER expresses the relation between the costs
and effects of one intervention compared with another
[42]. To address uncertainty in the ICER sampling distri-
bution, non-parametric bootstrapping will be carried out
[43]. Five thousand replications will be carried out for
each treatment comparison.
As the duration of the study was only 6 months, neither
costs nor outcomes were subject to discounting [42].
Discussion
The results of this study will provide valuable information
for health professionals and policy makers on effective-
ness and cost-effectiveness of a pharmaceutical interven-
tion programme in patients with depressive disorders. In
the case of proven effectiveness and cost-effectiveness, we
would recommend implementing this management inter-
vention into usual healthcare.
Below, design characteristics that involve potential threats
to reliability and validity are described.
Firstly, the naturalistic nature of the study and the wide
inclusion criteria generate a large inter-subject variability
that can reduce the ability to detect differences. On the
other hand, that may favour the generalization of the
results of this study.
Secondly, two situations may cause contamination bias.
Firstly, bias may occur due to the fact that participants of
the usual care group share pharmacies with those on the
intervention group. To limit this potential contamination
Table 3: Assessed side-effects
Asthenia/Lassitude/lncreased Fatigability
Sleepiness/Sedation
Tension/lnner Unrest
Increased Duration of Sleep
Reduced Duration of Sleep
Increased Dream Activity
Tremor
Increased Salivation
Reduced Salivation
Nausea/Vomiting
Diarrhoea
Constipation
Stomach cramp
Orthostatic Dizziness
Palpitations/Tachycardia
Headache
Increased Tendency to Sweating
Weight gain
Weight loss
Diminished Sexual Desire
Sexual dysfunctionPage 6 of 8
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BMC Public Health 2009, 9:284 http://www.biomedcentral.com/1471-2458/9/284bias, interviewers and pharmacists will remind patients
not to share information about the appointments with
their pharmacists or with other people participating in the
study. Secondly, pharmacists participating will receive
training in pharmaceutical care in depression which may
encourage them to also apply the programme to the con-
trol group. In order to limit this bias, pharmacists will be
asked to be especially careful not to contaminate the con-
trol group with pharmaceutical intervention.
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